Characteristic Study ID	Primarya endpoint(s)	Secondaryb endpoint(s)	Otherc endpoint(s)	Time points for outcome measurement
Aubertin‐Leheudre 2008	Fasting plasma LDL‐C	Adverse events, fasting plasma TC, HDL‐C, triglycerides	BMI, body weight, waist circumference, total FM, abdominal FM, visceral FM, REE, DEE, diastolic blood pressure, systolic blood pressure, HDL‐C/TC, fasting plasma glucose and insulin, HOMA2‐IR	6 months
Dewell 2002	‐	Fasting serum TC, triglycerides	‐	6 months
Gardner 2001	Fasting plasma LDL‐C	Adverse events, fasting plasma TC, HDL‐C, triglycerides	Androstenedione, BMI, oestradiol, estrone, FSH	12 weeks
Mackey 2000	Fasting serum LDL‐C	Fasting serum TC,HDL‐C, triglycerides	Body weight, FSH, LH, TSH, SHBG, osteocalcin, bone‐specific alkaline phosphatase	12 weeks
Wang 2005	Fasting blood LDL‐C	Fasting blood TC, HDL‐C, triglycerides	‐	3 months
Footnotes a,b verbatim statement in the publication; c not explicitly stated as primary or secondary endpoint(s) in the publication. "‐" denotes not reported. BMI: body mass index; DEE: daily energy expenditure; FFM: fat‐free mass; FM: fat mass; FSH: follicle‐stimulating hormone; HDL‐C: high‐density lipoprotein cholesterol; HOMA2‐IR: homeostasis model assessment; LDL‐C: low‐density lipoprotein cholesterol; LH: luteinizing hormone; REE: resting energy expenditure; SHBG: sex hormone binding globulin; TC: total cholesterol; TSH: thyroid‐stimulating hormone.